A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
UMC Utrecht
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
City of Hope Medical Center
Washington University School of Medicine
Columbia University
University of Arizona
Instituto de Investigacion Sanitaria La Fe
Stanford University
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Qianfoshan Hospital
Weprom
Wake Forest University Health Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
City of Hope Medical Center
Stanford University
Instituto do Cancer do Estado de São Paulo
Swiss Cancer Institute
CureOne
Stanford University
Wake Forest University Health Sciences
Mayo Clinic
Johns Hopkins Bloomberg School of Public Health
Northwestern University
Fox Chase Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Dartmouth-Hitchcock Medical Center
City of Hope Medical Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
Duke University